Not Yet RecruitingNot Applicable

Identification of Chemotherapy-induced Peripheral Neuropathy

26 participantsStarted 2025-11-01

Plain-language summary

The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Histologically proven breast cancer
✓. Previous treatment with taxane-based chemotherapy followed by adjuvant radiotherapy
✓. Moderate to severe or no CIPN according to the Utah Early Neuropathy Scale and the Total Neuropathy Score
✓. Female gender
✓. Age ≥18 years
✓. Written informed consent
✓. Capacity of the patient to consent

Exclusion criteria

✕. Disease-related skin disorders of the lower extremities (e.g., related to skin infections, bullous dermatoses, dermatitis, papulo-squamous skin disorders, or urticaria/erythema)
✕. Pregnancy, Lactation
✕. Expected non-compliance

What they're measuring

Number of participants with moderate to severe chemotherapy-induced peripheral neuropathy

Timeframe: from enrollment to clinical examination at 1 week

Trial details

NCT IDNCT07148336

SponsorUniversity Hospital Schleswig-Holstein

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-06-15

Contact for this trial

Dirk Rades, Prof Dr med

0049-451-500 dirk.rades@uksh.de

View on ClinicalTrials.gov More Breast Cancer trials